CN110191896B - 改进的血清白蛋白结合物 - Google Patents

改进的血清白蛋白结合物 Download PDF

Info

Publication number
CN110191896B
CN110191896B CN201880007313.6A CN201880007313A CN110191896B CN 110191896 B CN110191896 B CN 110191896B CN 201880007313 A CN201880007313 A CN 201880007313A CN 110191896 B CN110191896 B CN 110191896B
Authority
CN
China
Prior art keywords
serum albumin
seq
amino acid
single variable
immunoglobulin single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880007313.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110191896A (zh
Inventor
斯特凡妮·斯塔埃朗
索伦·斯特芬森
埃丽卡·莫里齐奥
安·瑟达贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Priority to CN202311123454.3A priority Critical patent/CN117285623A/zh
Publication of CN110191896A publication Critical patent/CN110191896A/zh
Application granted granted Critical
Publication of CN110191896B publication Critical patent/CN110191896B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880007313.6A 2017-01-17 2018-01-17 改进的血清白蛋白结合物 Active CN110191896B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311123454.3A CN117285623A (zh) 2017-01-17 2018-01-17 改进的血清白蛋白结合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762446988P 2017-01-17 2017-01-17
US62/446,988 2017-01-17
PCT/EP2018/051083 WO2018134235A1 (en) 2017-01-17 2018-01-17 Improved serum albumin binders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311123454.3A Division CN117285623A (zh) 2017-01-17 2018-01-17 改进的血清白蛋白结合物

Publications (2)

Publication Number Publication Date
CN110191896A CN110191896A (zh) 2019-08-30
CN110191896B true CN110191896B (zh) 2023-09-29

Family

ID=61521465

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880007313.6A Active CN110191896B (zh) 2017-01-17 2018-01-17 改进的血清白蛋白结合物
CN202311123454.3A Pending CN117285623A (zh) 2017-01-17 2018-01-17 改进的血清白蛋白结合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311123454.3A Pending CN117285623A (zh) 2017-01-17 2018-01-17 改进的血清白蛋白结合物

Country Status (21)

Country Link
US (2) US11414481B2 (cg-RX-API-DMAC7.html)
EP (3) EP3571225B1 (cg-RX-API-DMAC7.html)
JP (3) JP7219220B2 (cg-RX-API-DMAC7.html)
KR (2) KR102662499B1 (cg-RX-API-DMAC7.html)
CN (2) CN110191896B (cg-RX-API-DMAC7.html)
AU (2) AU2018209151B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019014599A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050575A1 (cg-RX-API-DMAC7.html)
DK (1) DK3571225T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991459T3 (cg-RX-API-DMAC7.html)
FI (1) FI3571225T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241469T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068790T2 (cg-RX-API-DMAC7.html)
IL (2) IL312292A (cg-RX-API-DMAC7.html)
LT (1) LT3571225T (cg-RX-API-DMAC7.html)
MX (2) MX2019008496A (cg-RX-API-DMAC7.html)
PT (1) PT3571225T (cg-RX-API-DMAC7.html)
RS (1) RS66117B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201906264YA (cg-RX-API-DMAC7.html)
SI (1) SI3571225T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018134235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL250396B (en) 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
US11414481B2 (en) * 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
LT3571224T (lt) * 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
IL293561A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
IL293554A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising an immunoglobulin with one variable domain that target tnfa and ox40l
KR20220123237A (ko) 2019-12-09 2022-09-06 아블린쓰 엔.브이. Il-13 및 tslp를 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩타이드
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
IL296767A (en) 2020-03-30 2022-11-01 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
JP2023544124A (ja) 2020-09-25 2023-10-20 アブリンクス エン．ヴェー． Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
US11897951B2 (en) * 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
JP2024546916A (ja) 2021-12-17 2024-12-26 アブリンクス エン．ヴェー． ＴＣＲαβ、ＣＤ３３及びＣＤ１２３を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
WO2023242247A1 (en) 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
KR102822958B1 (ko) * 2023-05-23 2025-06-20 대한민국(해양경찰청 해양경찰연구센터장) 고래 불법포획 감식용 신속진단키트
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025217488A1 (en) * 2024-04-12 2025-10-16 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
CN101965364A (zh) * 2007-02-08 2011-02-02 杜门蒂斯有限公司 抗血清白蛋白的抗体单个可变区
CN104203975A (zh) * 2011-06-23 2014-12-10 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
EP2944653A1 (en) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
CN100439400C (zh) 2003-01-10 2008-12-03 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
US20090191217A1 (en) 2004-12-02 2009-07-30 De Wildt Ruud M Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
DK1888641T3 (da) 2005-05-18 2012-04-23 Ablynx Nv Serumalbuminbindende proteiner
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
TW200730539A (en) 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
AU2006321367B2 (en) 2005-12-01 2011-11-03 Domantis Limited Competitive domain antibody formats that bind Interleukin 1 Receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110189203A1 (en) 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
BR112012001681A2 (pt) 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
CN104147611A (zh) 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
WO2012020143A1 (en) 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
EP2606065A2 (en) 2010-08-20 2013-06-26 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2759936T3 (es) * 2011-06-23 2020-05-12 Ablynx Nv Proteínas de unión a albúmina sérica
US20150344568A1 (en) * 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
KR102162413B1 (ko) 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
US20130129727A1 (en) * 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
DK3143042T3 (da) 2014-05-16 2020-08-31 Ablynx Nv Forbedrede variable immunoglobulindomæner
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
DK3294768T3 (da) 2015-05-13 2019-11-11 Ablynx Nv T-celle-rekrutterende polypeptider baseret på tcr-alfa/beta-reaktivitet
PL3374392T3 (pl) * 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
JP7256011B2 (ja) 2015-11-27 2023-04-11 アブリンクス エン．ヴェー． Ｃｄ４０ｌを阻害するポリペプチド
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
LT3571224T (lt) * 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
WO2025061919A1 (en) * 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
CN101965364A (zh) * 2007-02-08 2011-02-02 杜门蒂斯有限公司 抗血清白蛋白的抗体单个可变区
CN104203975A (zh) * 2011-06-23 2014-12-10 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
EP2944653A1 (en) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains

Also Published As

Publication number Publication date
JP7219220B2 (ja) 2023-02-07
KR20240013861A (ko) 2024-01-30
ES2991459T3 (es) 2024-12-03
US20230060574A1 (en) 2023-03-02
WO2018134235A8 (en) 2024-03-21
MX2023005374A (es) 2023-05-22
FI3571225T3 (fi) 2024-10-31
SI3571225T1 (sl) 2025-03-31
RU2019125831A (ru) 2021-02-19
RS66117B1 (sr) 2024-11-29
AU2018209151A1 (en) 2019-07-25
EP4442709A2 (en) 2024-10-09
EP4442709A3 (en) 2024-12-25
US11414481B2 (en) 2022-08-16
JP2023025232A (ja) 2023-02-21
KR20190104608A (ko) 2019-09-10
EP4442707A3 (en) 2024-12-25
KR102662499B1 (ko) 2024-05-02
IL267894B1 (en) 2024-06-01
WO2018134235A1 (en) 2018-07-26
US20190367597A1 (en) 2019-12-05
LT3571225T (lt) 2024-11-11
SG10202108972RA (en) 2021-09-29
CA3050575A1 (en) 2018-07-26
AU2025203430A1 (en) 2025-06-05
RU2019125831A3 (cg-RX-API-DMAC7.html) 2021-03-09
AU2018209151B2 (en) 2025-02-27
PT3571225T (pt) 2024-11-05
HUE068790T2 (hu) 2025-01-28
CN110191896A (zh) 2019-08-30
EP4442707A2 (en) 2024-10-09
IL312292A (en) 2024-06-01
CN117285623A (zh) 2023-12-26
IL267894B2 (en) 2024-10-01
DK3571225T3 (da) 2024-11-04
IL267894A (en) 2019-09-26
EP3571225A1 (en) 2019-11-27
JP2020515518A (ja) 2020-05-28
HRP20241469T1 (hr) 2025-01-03
MX2019008496A (es) 2019-09-18
BR112019014599A2 (pt) 2020-03-03
JP2025026992A (ja) 2025-02-26
EP3571225B1 (en) 2024-08-07
SG11201906264YA (en) 2019-08-27
JP7628996B2 (ja) 2025-02-12

Similar Documents

Publication Publication Date Title
CN110191896B (zh) 改进的血清白蛋白结合物
JP7585272B2 (ja) 改善された血清アルブミン結合剤
CN110049997A (zh) 改进的血清白蛋白结合免疫球蛋白单可变结构域
HK40117444A (en) Improved serum albumin binders
HK40118030A (en) Improved serum albumin binders
HK40116819A (en) Improved serum albumin binders
HK40119626A (en) Improved serum albumin binders
HK40017968B (en) Improved serum albumin binders
HK40017968A (en) Improved serum albumin binders
HK40018516B (en) Improved serum albumin binders
HK40018516A (en) Improved serum albumin binders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment